Title:Therapeutic Potential of Mesenchymal Stem Cells or their Secretome in Diabetic Mice with or without Preconditioning Treatment
Volume: 20
Issue: 1
Author(s): Shivani M. Desai*, Ramesh R. Bhonde, Addepalli Veeranjaneyulu*, Avinash Sanap, Surabhi Jarare, Snehal Satpute, Omkar Janjire, Anusaya Soundankar, Niyaz Ahmed and Krushna Abhale
Affiliation:
- Clinical Research and Pharmacovigilance, Serum Institute of India Pvt. Ltd., Hadapsar, Pune, India
- Department of Pharmacology, Dr. D.Y. Patil Institute of
Pharmaceutical Sciences and Research, Pimpri, Pune, India
Keywords:
Type 1 diabetes mellitus, umbilical cord-derived mesenchymal stem cells (UCMSC), streptozotocin model, immunomodulation, pancreatic regeneration, C-peptide.
Abstract:
Background: Type 1 diabetes mellitus (T1DM) is an autoimmune disease with difficult
management, affecting the quality of life. Stem cell therapy has been proven to have regenerative
ability. Using the existing stem cell therapy and modifying it, the current study aims to
evaluate the effect of umbilical cord-derived mesenchymal stem cells (UCMSC), condition media
(CM), and UCMSC and CM preconditioned with methotrexate, reservetrol, and vitamin D
for its ability to manage T1DM in Swiss albino mice.
Materials & Methods: Disease condition was established in the animals by using a diabetesinducing
agent streptozotocin (STZ). Then the animals were grouped into normal control, disease
control, standard, and test groups; and the treatments were given accordingly. The total
study period for this experiment was 28 days. During this period, the animals were supervised
for blood glucose levels, food-water intake, and body weight twice a week. At the end of 28
days, the biochemical estimations for serum insulin level, C-peptide, pro-inflammatory cytokines,
and anti-inflammatory cytokines level were done. Also, histopathology of the pancreas
was performed.
Results: The test groups showed a significant decline in the blood glucose level, an increase
in C-peptide level, and a decrease in pro-inflammatory cytokines as compared to the
disease group. A statistically significant change was not observed within the groups in
terms of serum insulin and anti-inflammatory cytokine levels. There were improvements
in diabetic symptoms in treatment groups, such as polyphagia, polydipsia, and weight
loss. Treatment groups also showed pancreatic regeneration, indicating improved insulin
secretion.
Conclusion: In the present study, we concluded that UCMSC, CM, and UCMSC and CM
preconditioned with synthetic and natural immunosuppressants and immunomodulators have
the ability to regenerate damaged pancreatic beta cells and have an antidiabetic activity,
along with an immunomodulating effect. This therapy is a promising choice for future
research.
